13550_2020_600_MOESM2_ESM.tif (69.5 kB)
Additional file 2 of Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
figure
posted on 2020-02-12, 04:42 authored by Tom Bäck, Karin Jennbacken, Malin Hagberg Thulin, Sture Lindegren, Holger Jensen, Tove Olafsen, Paul Yazaki, Stig Palm, Per Albertsson, Jan-Erik Damber, Anna Wu, Karin WelénAdditional file 2: Figure S2. The immunoreactive fraction (IRF) of the minibody after radiolabeling with 211At was analyzed in a viable cell assay previously described. Serial 1:2 dilutions of PC3- PSCA cell suspensions (0.15625 to 10 million cells per mL) were incubated with 5 ng 211At- A11.1 at 8ºC. After a 3 hour incubation, centrifugation and washing of the pellets, the IRF was calculated from the double-inverse plot of specific binding (B/T) over cell concentration. The plot above corresponds to a IRF of 0.67.
